Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Treasury Shares (2019 - 2025)

Cogent Biosciences' Treasury Shares history spans 4 years, with the latest figure at $4.0 million for Q4 2025.

  • Quarterly Treasury Shares rose 47.02% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 47.02% year-over-year, with the annual reading at $4.0 million for FY2025, 47.02% up from the prior year.
  • Treasury Shares came in at $4.0 million for Q4 2025, up from $2.7 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $4.0 million in Q4 2025 to a low of $2.5 million in Q4 2023.
  • The 3-year median for Treasury Shares is $2.7 million (2024), against an average of $3.1 million.
  • Year-over-year, Treasury Shares increased 8.56% in 2024 and then surged 47.02% in 2025.
  • Cogent Biosciences' Treasury Shares stood at $2.5 million in 2023, then grew by 8.56% to $2.7 million in 2024, then surged by 47.02% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for COGT's Treasury Shares are $4.0 million (Q4 2025), $2.7 million (Q4 2024), and $2.5 million (Q4 2023).